600 patients66,869 observations120 daysLIVE
← Patients

Patient P-01364

Synthetic patientNBL-101 · Day 116 · 55–64 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Stable
Inflammatory state
Unstable
Nutritional resilience
Stable
Discontinuation risk
71%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 started — Baseline state S14
  2. Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  3. Day 51 GI-04 recommended — GI Support Protocol GI-04
  4. Day 52 Patient accepted — Started GI-04 in the companion
  5. Day 60 GI symptom burden −18% vs expected — GI Support Protocol GI-04
  6. Day 66 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days
  • Inflammatory activity+2
  • Nutritional resilience+2

What helped?

  • GI Support Protocol GI-04Day 51
    Result: symptom burden −18%
LIFE OS recommendation
Dietary Support Protocol NP-02
62%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
54.4/100
improving · -3.4 vs previous 14 d
Toxicity
Blood
54.4/100
worsening · +7.3 vs previous 14 d
Sleep quality
Wearable
27.5/100
improving · +1.9 vs previous 14 d
Energy level
Daily log
2.6/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
6.6/10
stable · -0.0 vs previous 14 d
Steps
Wearable
5,695
stable · +9 vs previous 14 d
Adherence
Companion
49.4 %
stable · -1.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 29 from the failing basin, 60 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 76%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 76%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 76%
Would not help
  • Keep simple carbs low
    GI +4.3 next day on high-intake days · n 22
  • Keep fibre low
    GI +4.1 next day on high-intake days · n 17
  • Keep histamine low
    GI +4 next day on high-intake days · n 22
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Simple carbohydrates
    +4.3detractor · 95%
  • Insoluble fibre
    +4.1detractor · 95%
  • Histamine load
    +4detractor · 95%
  • Dietary fat load
    +3.9detractor · 95%
  • Alcohol
    +3.5detractor · 95%
  • Spicy / capsaicin
    -0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity ↓80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 54 and rising
  • Butyrate / short-chain fatty acid production ↓80
    • MicrobiomeButyrate capacity 25/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling ↑60
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 59
    • WearableHRV 17 ms, trending down
  • Autonomic recovery ↓25
    • WearableResting HR 80 bpm
  • Drug metabolism and exposure ↑20
    • BloodToxicity index 54
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 1.9 · butyrate capacity 25/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
17 ms
Sleep
6.8 h
Steps
5,798
Resting HR
81 bpm
Daily log: GI score 54, nutritional resilience 43, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0132745%S01GI-04improved56
P-0181343%S01NP-02no change40
P-0168836%S01GI-04improved40
P-0131033%S01——57
P-0187727%S01CR-01improved67
P-0160421%S01——71
P-0182121%S01——58
P-0182321%S01——57
P-0163540%S02GI-04improved49
P-0145235%S02GI-04improved46
P-0145930%S02——51
P-0149821%S02——56